All News

The investigators hope to pursue a human vaccine in order to improve upon the already existing vaccines.

Ronna Hauser, PharmD, Senior Vice President of Policy & Pharmacy Affairs at NCPA, provides insights into President Trump’s most recent executive order regarding manufacturer drug prices.

Investigators report that patients experience weight loss with a reduced weekly dosage of the glucagon-like peptide-1 (GLP-1).

Abbott’s continuous glucose monitoring system is the first to show a reduction in cardiovascular complication severity.

However, investigators find many gaps remaining in care for patients in relation to race, ethnicity, and disabilities.

Investigators also find that patients diagnosed with type 1 diabetes later in life do not have a better prognosis compared to those diagnosed earlier.

Investigators also found that nocturnal hypoglycemia is a strong predictor of daytime hypoglycemia.

Pharmacist-led interventions improve medication adherence compared with the usual care for patients with heart failure and type 2 diabetes.

Semaglutide resulted in a significant reduction in the risk of MACE within the first 3 months of treatment compared to placebo.

Greg Miller, RPh, discussed the past, present, and future of the Inflation Reduction Act and key insights pharmacists should understand in order to keep up with the legislation.

In a phase 3 study, 57% of patients treated with icotrokinra achieved an Investigator's Global Assessment score of 1 or 0 and a grade 2 or more improvement at week 16.

Tirzepatide (Zepbound) demonstrated superiority compared to semaglutide (Wegovy) across the primary end point and 5 key secondary end points.

The order is set to make patients’ prescription costs similar to other nations with the lowest-priced drugs in the world.

Investigators find that unhealthy eating and inadequate or excessive sleeping duration could contribute to developing diabetic nephropathy.

Douglas Hoey, CEO of NCPA, discusses what independent pharmacies can do to handle an influx of patients and what the chain’s situation means for the pharmacy landscape.

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss the basics of AI and how it’s assisting with compliance.

The therapy achieved positive results during a phase 2b trial on the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score.

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

A phase 2 study found 95% of patients achieved a sustained virologic response at 12 weeks regardless of treatment adherence.

Selarsdi is interchangeable for all indications of ustekinumab, including treatment of psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.

The use of electronic prescribing can also bridge the gap in clinical history, which can help pharmacists be aware of adverse drug reactions and medication interactions.

Among patients treated with buprenorphine, 25.4% experienced adverse pregnancy outcomes, compared to 30.8% in the untreated group.

Vaccination changes serotype distribution from vaccine-type serotypes to nonvaccine-type serotypes.

Sarah Thomas and David Skomo of HealthDyne discuss some of the most useful innovations that have been helpful for pharmacies.

Casey Koch, PharmD, MBA, BCACP, clinical pharmacy coordinator at SelectHealth discusses how pharmacists can reduce patient burden.